SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma

11 March 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS ...

Read more →

Japan approves two gene treatments in bid to catch up

21 February 2019 - Potential revolutionary treatments have exorbitant price tags. ...

Read more →

Gilead receives approval in Canada for Yescarta (axicabtagene ciloleucel) CAR T therapy for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

19 February 2019 - Yescarta is a chimeric antigen receptor T-cell therapy that is custom-made for each patient from his or ...

Read more →

CMS proposes coverage with evidence development for chimeric antigen receptor (CAR) T-cell therapy

15 February 2019 - Proposed decision would provide nationwide consistency in CMS’s coverage of the innovative new cancer therapy, to ...

Read more →

Yescarta rejected among other SMC decisions

12 February 2019 - Gilead's CAR-T therapy Yescarta (axicabtagene ciloleucel) has been rejected by the Scottish Medicines Consortium (SMC) for ...

Read more →

SMC - February 2019 decisions

11 February 2019 - A medicine used to treat a rare blood cancer in children and young adults has today  ...

Read more →

NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma

1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...

Read more →

Will price be a barrier to new cancer immunotherapy?

19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...

Read more →

Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends

16 January 2019 - A groundbreaking gene therapy for cancer could cost the Canadian health care system more than $400 ...

Read more →

Statement from FDA Commissioner and Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies

15 January 2019 - The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced ...

Read more →

Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments

7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...

Read more →

Biotech proposes paying for pricey drugs by instalment

8 January 2019 - Bluebird Bio develops plan to sell gene-replacement therapy with annual payments contingent on continued effectiveness. ...

Read more →

Paying it forward: man pledges $1million to get life-saving cancer treatment in NZ

31 December 2018 - The Herald speaks with Kiwis who have been on the edge of death, had their world ...

Read more →

CRISPR Therapeutics and Vertex announce FDA fast track designation for CTX001 for the treatment of sickle cell disease

4 January 2019 - CRISPR Therapeutics and Vertex Pharmaceuticals today announced that the U.S. FDA has granted fast track Designation for ...

Read more →

Revolutionary' cancer drug using genetically modified cells approved

19 December 2018 - A revolutionary cancer therapy that supercharges a patient's immune cells to hunt and destroy cancer cells ...

Read more →